Mavenir Confirms Refocus Strategy on Mobile Core and AI Vision With Expanded Leadership Team to Accelerate AI-Native Network Strategy
Mavenir Confirms Refocus Strategy on Mobile Core and AI Vision With Expanded Leadership Team to Accelerate AI-Native Network Strategy Leave a reply RICHARDSON, Texas, Dec.
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks
Bitget October 2025 Protection Fund Maintains $741M Average Despite Slumptober
Bitget October 2025 Protection Fund Maintains $741M Average Despite Slumptober Leave a reply Bitget October 2025 Protection Fund Maintains $741M Average Despite Slumptober Bitget October
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025
EBC Financial Group Recognised as Best Broker for Execution at Professional Trader Awards 2025 Leave a reply Recognition follows a vote by professional and active
Private Healthcare Costs Are Rewriting the Map for Migrating Millionaires, New Data Shows
Private Healthcare Costs Are Rewriting the Map for Migrating Millionaires, New Data Shows Leave a reply LONDON, Dec. 08, 2025 (GLOBE NEWSWIRE) — A sharp
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting
Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH)